BUSINESS

• Chugai Seeks Vabysmo Label Expansion for RVO
  April 28, 2023

• 374 Chugai Employees Apply for Voluntary Redundancy Program
  April 28, 2023

• Global PIII Launched for Novel β-Lactamase Inhibitor Nacubactam: Meiji
  April 27, 2023

• Pfizer Japan Files Combo Antibiotic Containing β-Lactamase Inhibitor
  April 27, 2023

• Stelues Data in Japanese to Be Gathered via Normal Pharmacovigilance Activities: Pfizer
  April 27, 2023

• Pfizer Japan Files Genotropin for Prader-Willi Syndrome
  April 26, 2023

• HUYA’s Hiyasta Enters PIII Melanoma Study in Japan: Meiji
  April 26, 2023

• Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
  April 26, 2023

• Sumitomo Curbs Shipments of Diabetes Hopeful Twymeeg on More-Than-Expected Demands
  April 25, 2023

• Santen to Forge Ahead with Structure Reform, Revenue Revamp to Upscale Growth
  April 25, 2023

• Actemra Approved in Taiwan for Hospitalized COVID-19 Patients: Chugai
  April 25, 2023

• Takeda Installs Chief Tech Officer Role as It Revs Up Digital Drive: CEO
  April 24, 2023

• Mitsubishi Sent Letter Agreeing to Call Off Muse Cell License Deal: Researchers
  April 24, 2023

• US FDA Extends Target Date for Daiichi Sankyo’s FLT3 Inhibitor by 3 Months
  April 24, 2023

• Drug Makers’ New Grad Hiring in Japan Up 5.8%, Rising for 1st Time since FY2020
  April 21, 2023

• Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
  April 21, 2023

• Moderna Looks to Start Japan Production of mRNA Vaccines around 2027
  April 20, 2023

• Lonsurf-Bevacizumab Combo Gets FDA’s Priority Review in Colorectal Cancer: Taiho
  April 20, 2023

• Ono Aims Higher with Aggressive Open Innovation in Drug Discovery
  April 19, 2023

• Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
  April 19, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 138
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• 146
• …
• Next ›
• 最終 »